Mind Medicine Inc Ordinary Shares (Sub Voting) MNMD 深 滬
等待開盤 12-24 09:30:00 美东时间
14.02
+0.720
+5.41%
華盛通- 最 高14.28
- 今 開13.65
- 成交量 317.61万股
- 最 低 13.48
- 昨 收 13.30
- 總市值 10.67亿
- 52周最高 14.43
- 市盈率 靜 --
- 換手率 4.17%
- 52周最低 4.70
- 委 比 -3.29%
- 總股本 7608.79万
- 歷史最高 86.55
- 量 比 1.02
- 振 幅 6.02%
- 歷史最低 2.20
- 每 手 1
- 風險率 2.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
今天 11:17
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
Psyence Biomedical Ltd., a biopharmaceutical company, announced that its nature-derived psilocybin product has been approved for use in its Phase IIb clinical trial for treating Adjustment Disorder in cancer patients. With $9.5 million in cash reserves and no debt, the company is vertically integrated, positioning it as a leader in the psychedelics sector. The trial, conducted at multiple sites, aims to evaluate psilocybin-assisted psychotherapy ...
12-19 12:00
Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study
Vistagen shares plunge after its Phase 3 fasedienol trial for social anxiety failed to meet the primary endpoint, despite favorable safety data.
12-18 01:42
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
电话会总结 ｜ MindMed(MNMD)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据MindMed业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **现金状况：** - 截至2025年9月30日，现金、现金等价物和投资总额为2.091亿美元 - 第四季度完成股权融资，募集资金总额2.589亿美元，扣除费用后净收益2.428亿美元 **费用支出：** - 研发费用：2025年为3,100万美元，2024年为1,720万美元 - 一般管理费用：2025年为1,470万美元，2024年为760万美元 - 净亏损：2025年为6,730万美元，2024年为1,370万美元 **认股权证收益：** - 2025年认股权证行权带
11-07 12:24
Mind Medicine Q3 EPS $(0.78) Misses $(0.50) Estimate
Mind Medicine (NASDAQ:MNMD) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.50) by 56 percent. This is a 188.89 percent decrease over losses of $(0.27) per share from the
11-07 05:04
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care
Psyence BioMed has achieved a significant milestone by successfully dosing multiple patients in its Phase IIb clinical trial evaluating nature-derived psilocybin for treating Adjustment Disorder in palliative care. The trial, which includes three active sites in Australia, employs a rigorous design to meet regulatory standards and generate reliable data. This advancement underscores Psyence BioMed's leadership in psychedelic drug development and ...
11-06 12:00
MindMed Issues Inducement Grants to New Employees
The latest update is out from Mind Medicine ( ($MNMD) ). MindMed announced the ...
11-04 09:09
